CD274 and neoplasm: In a phase I clinical trial of 22 patients with advanced melanoma, giving ipilimumab after hypofractionated radiotherapy to a single tumor lesion also led to partial responses in the non‐irradiated tumor, with a co‐clinical murine model demonstrating the best efficacy with triple therapy including anti‐PD‐L1.123